1. Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors.
- Author
-
Gubbi, Sriram, Vijayvergia, Namrata, Yu, Jian Q, Klubo-Gwiezdzinska, Joanna, and Koch, Christian A.
- Subjects
IMMUNE checkpoint inhibitors ,NEUROENDOCRINE tumors ,PROGRAMMED cell death 1 receptors ,PEPTIDE receptors ,PROTEIN-tyrosine kinase inhibitors ,MTOR inhibitors ,MEDULLARY thyroid carcinoma - Abstract
Neuroendocrine tumors (NETs) occur in various regions of the body and present with complex clinical and biochemical phenotypes. The molecular underpinnings that give rise to such varied manifestations have not been completely deciphered. The management of neuroendocrine tumors (NETs) involves surgery, locoregional therapy, and/or systemic therapy. Several forms of systemic therapy, including platinum-based chemotherapy, temozolomide/capecitabine, tyrosine kinase inhibitors, mTOR inhibitors, and peptide receptor radionuclide therapy have been extensively studied and implemented in the treatment of NETs. However, the potential of immune checkpoint inhibitor (ICI) therapy as an option in the management of NETs has only recently garnered attention. Till date, it is not clear whether ICI therapy holds any distinctive advantage in terms of efficacy or safety when compared to other available systemic therapies for NETs. Identifying the characteristics of NETs that would make them (better) respond to ICIs has been challenging. This review provides a summary of the current evidence on the value of ICI therapy in the management of ICIs and discusses the potential areas for future research. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF